Dr. Joobin khadamy is Researcher at Eye Research Center, Rasoul Akram hospital, Iran university of Medical science (IUMS). He is member of Gavin Ophthalmology (GOPH) Editorial Board. He is reviewer of Journal of Current Ophthalmology and Journal of Clinical and experimental Ophthalmology. He has participated in international congresses by oral and poster presentations. He is Iranian board of ophthalmology certified. He has received his ophthalmology specialty at IUMS. He has received his MD at Tehran University of Medical Science(TUMS). He was nominated as exceptional talent of TUMS. He has authored number of high quality articles indexed in pubmed, sciencedirect, etc, as well as book titles in public health matters and biology. He is practicing ophthalmology at Vali-e-Asr hospital, Birjand University of Medical Science), Current.
Current study designed to report visual outcomes and corneal biomechanical changes after Intacs SK implantation in keratoconic eyes. In a prospective interventional case-series comprised 32 keratoconic eyes of 25 patients (mean age: 24 years) with a clear central cornea and contact lens intolerance. Intacs SK was implanted using a Technolas femtosecond laser platform. Uncorrected (UDVA) and corrected (CDVA) distance visual acuity, refraction, manifest refraction spherical equivalent (MRSE), keratometry, central corneal thickness (CCT), corneal hysteresis (CH) and corneal resistance factor (CRF) were measured preoperatively, and at 1, 3 and 6 months postoperatively. The mean UDVA improved from 0.81±0.3 logMAR preoperatively to 0.53±0.2 logMAR at 6 months (P<.001). At 6 months, MRSE was better significantly only in eyes with moderate KCN (mean change=+2.61±0.54 diopter [D]; P<.001). A significant improvement in sphere (mean change= +1.92±0.37 D; P<.001) and mean keratometry reading (mean change= -3.34±0.47; P<.001) was observed. Mean CCT increased from 446.1±38 μm preoperatively to 462.2±50 μm at 6 months (P<.001). CRF decreased from 6.5 ± 1.6 mmHg to 5.9 ± 1.1 mmHg at 6 months (P=.02). CDVA, cylinder and CH did not change significantly (P = .48, .203 and .55 respectively). 19 eyes (60%) gained ≥2 lines of UDVA while 5 eyes (16%) lost ≥2 lines of UDVA. Generally, visual, refractive and keratometric indices improved remarkably in a parallel fashion. CRF was inversely correlated with CCT. Fluctuations in corneal hydration might explain trends of changes in biomechanical parameters and CCT during the early postoperative months.
Dr. Fawaaz Almamoori isHead Of Medical Retina Department in Eye Specialty Hospital (Amman, Jordan) and Head Of Scientific Ophthalmology Training Program in Eye Specialty Hospital. He is also the Advisory Board Member of ( Allergan, Novartis and Bayer). Dr. Almamoori is a certified Femtosecond (LenSix) cataract surgeon and Certified Femtosecond (Vectus) cataract Surgeon. His area of interests includes Diabetic Retinopathy, AMD(Age Related Macular Degeneration) and Retinal vascular disease.\r\n\r\n
INTRODUCTION\r\nRetinitis pigmentosa is a clinically & genetically diverse group of diffuse retinal dystrophies that initially affecting rod with subsequent degeneration of cones,\r\nMaculopathy is one of the complications of RP that affecting vision and usually takes different types 1.(Atrophic),2.(Cystoid Macular Edema) 3.(Macular retraction), The prevalence of CME was 52% in AD RP , 39 % in AR RP and 35% in XL.\r\n\r\nMETHODS\r\nWe retrospectively review a 24y old male patient that presented with bilateral refractory cystoid macular edema secondary to RP which is not responding to topical carbonic anhydrase inhibitor and multiple anti VEGF injections of Lucentis in both eyes,the patient underwent bilateral 0.7 mg intravitreal dexamethason(OZURDEX) implant of 1 week apart, the spectral domain OCT was performed before and one month after OZURDEX injection and to assess the efficacy of intravitreal steroid implants in treatment of refractory CMO in RP.\r\n\r\nRESULTS\r\nThe Spectral Domain OCT after 1 month of injection showed a significant anatomical and functional improvements,CMT improved from 314 um to 233 um in the right eye and from 590 um to 207 um in the left eye. The BCVA improved from 6/18 to 6/9 in the right eye and from CF 1 meter to 6/60 in the left eye.\r\n\r\nCONCLUSION\r\nIt seems that the refractory CMO in RP is mostly inflammatory driven, for this reason it shows a dramatic response to intravitreal steroids, in our case, the patient has received multiple anti VEGF injections of Lucentis with no improvment,but he responded very well anatomically and functionally to intravitreal steroid implant of OZURDEX,the results in our case was matching other small case series results,EX:In retrospective study of Ozdemir et al reported the efficacy of intravitreal steroid in a group of five eye of five patients. Further preferably randomized trails may establish the place of intravitreal dexamethason in the treatment of refractory CME related to RP\r\n